Fmr LLC Raises Holdings in Masimo Co. (NASDAQ:MASI)

FMR LLC boosted its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 19.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 8,097,454 shares of the medical equipment provider's stock after purchasing an additional 1,340,836 shares during the quarter. FMR LLC owned about 15.12% of Masimo worth $1,338,509,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MASI. Vanguard Group Inc. raised its stake in shares of Masimo by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock worth $758,182,000 after purchasing an additional 66,215 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after buying an additional 943,001 shares during the last quarter. State Street Corp raised its position in Masimo by 0.7% in the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock worth $191,837,000 after buying an additional 10,179 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Masimo by 1,276.9% during the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock valued at $156,604,000 after acquiring an additional 878,587 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Masimo by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 801,125 shares of the medical equipment provider's stock valued at $132,465,000 after acquiring an additional 8,239 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Remove Ads

Masimo Stock Performance

Shares of NASDAQ:MASI traded up $2.41 during midday trading on Friday, hitting $153.90. The company had a trading volume of 729,386 shares, compared to its average volume of 655,434. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a fifty day moving average of $170.60 and a two-hundred day moving average of $164.27. The company has a market cap of $8.32 billion, a price-to-earnings ratio of 106.14 and a beta of 1.28. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. On average, equities research analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.

Analyst Upgrades and Downgrades

MASI has been the topic of a number of research analyst reports. Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company raised their price target on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler upped their price objective on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.